Q4 EPS Estimates for AstraZeneca Lifted by Leerink Partnrs

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Stock analysts at Leerink Partnrs lifted their Q4 2025 earnings estimates for AstraZeneca in a note issued to investors on Monday, April 21st. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of $1.12 per share for the quarter, up from their prior forecast of $1.11. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for AstraZeneca's FY2026 earnings at $5.11 EPS.

Several other analysts also recently weighed in on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They issued an "overweight" rating for the company. UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Finally, BNP Paribas initiated coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of "Buy" and a consensus target price of $88.00.

AstraZeneca Price Performance

NASDAQ:AZN traded up $0.11 during mid-day trading on Wednesday, reaching $69.68. The stock had a trading volume of 4,781,970 shares, compared to its average volume of 5,174,111. The stock has a market capitalization of $216.11 billion, a P/E ratio of 30.84, a P/E/G ratio of 1.42 and a beta of 0.49. The firm has a 50 day moving average price of $72.33 and a two-hundred day moving average price of $70.16. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca has a one year low of $61.24 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Nordea Investment Management AB bought a new stake in AstraZeneca in the 4th quarter worth approximately $754,000. Diversify Wealth Management LLC lifted its position in AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock valued at $295,000 after purchasing an additional 153 shares during the last quarter. Ameritas Advisory Services LLC grew its stake in shares of AstraZeneca by 25.9% in the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company's stock worth $622,000 after buying an additional 1,949 shares in the last quarter. Oak Ridge Investments LLC increased its holdings in shares of AstraZeneca by 5.4% in the 4th quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company's stock worth $9,433,000 after buying an additional 7,341 shares during the last quarter. Finally, Asio Capital LLC lifted its holdings in shares of AstraZeneca by 11.6% in the 4th quarter. Asio Capital LLC now owns 53,541 shares of the company's stock valued at $3,508,000 after acquiring an additional 5,569 shares during the last quarter. Institutional investors own 20.35% of the company's stock.

AstraZeneca Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Investors of record on Friday, February 21st were issued a $1.03 dividend. This is a boost from AstraZeneca's previous semi-annual dividend of $0.49. This represents a yield of 2%. The ex-dividend date of this dividend was Friday, February 21st. AstraZeneca's dividend payout ratio (DPR) is currently 91.15%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.